Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Immunocore to Present at 32nd Annual JP Morgan Healthcare Conference

Published: Thursday, January 16, 2014
Last Updated: Thursday, January 16, 2014
Bookmark and Share
Company to provide an update on lead programme for melanoma.

Immunocore Limited has announced that it will present at the 32nd annual JP Morgan Healthcare Conference on Thursday 16 January 2014 at 11:30 am (Pacific Time) at the Westin St Francis Hotel, San Francisco.

James Noble, Chief Executive Officer, will present a corporate update and data from Immunocore’s most advanced ImmTAC programme, IMCgp100, for the treatment of late stage melanoma.

Phase I testing was completed in late 2013, with promising early signs of efficacy indicated, and the company has initiated a Phase IIa trial in the UK and USA designed to optimize the dosing regimen and maximize the efficacy of IMCgp100.

Last week Immunocore has announced its third partnership deal in six months - an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca.

Both companies will research and develop novel cancer therapies using Immunocore’s ImmTAC technology.

Immunocore’s novel bi-specific biologics platform exploits the power of the body’s own immune system to find and kill diseased cells. ImmTACs direct a patient’s T cells to specifically destroy only the cancerous cells, avoiding damage to healthy cells.

Immunocore also has major discovery collaborations ongoing with leading pharmaceutical companies Genentech and GlaxoSmithKline.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Immunocore Appoints Dr Eliot Forster as Chief Executive Officer
Immunocore Limited has announced the appointment of Dr Eliot Forster as Chief Executive Officer with immediate effect.
Monday, January 12, 2015
Immunocore and MedImmune Win the SCRIP Award
Immunocore and MedImmune are working together to generate ImmTACs against selected cancer targets.
Thursday, December 11, 2014
Immunocore and Lilly Enter Immunotherapy Agreement
Agreement to co-discover and co-develop novel cancer therapies.
Thursday, July 17, 2014
Immunocore and MedImmune Enter Immunotherapy Agreement
Companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer technology.
Wednesday, January 08, 2014
Immunocore Appoints New Chairman of the Board
Dr Jonathan Knowles appointed as Company’s new executive Chairman of the Board of Directors.
Monday, November 18, 2013
Immunocore Appoints Chairman
Immunocore Limited announced the appointment of Dr Jonathan Knowles as the new executive Chairman of the Board of Directors with immediate effect.
Thursday, November 14, 2013
Immunocore Achieves Research Milestone in GSK Collaboration
Under the agreement announced in July, Immunocore will receive up to £142 million in pre-clinical milestone payments across the targets.
Thursday, November 07, 2013
Immunocore Named One of Fierce 15 Leading Biotechs of 2013
Immunocore ranked among the top private biotech firms globally.
Thursday, September 26, 2013
Immunocore Signs Research and Licensing Agreement with GlaxoSmithKline
Companies collaborate to discover ImmTACs against novel targets.
Tuesday, July 09, 2013
Immunocore Announces Appointment of Eva-Lotta Allan to the Board
New position will strengthen management team as company expands operations.
Thursday, May 02, 2013
Revolutionary New Cancer Targeting Technology Described in Nature Medicine
Immunocore scientists manage to overcome cancer problem by boosting the ability of cancer-specific TCRs.
Monday, May 07, 2012
Clinical Trials of New Treatment for Advanced Melanoma In UK and USA
Researchers at Immunocore Limited have announced that IMCgp100, a targeted therapeutic for the treatment of advanced metastatic melanoma, has received regulatory and ethics approval and has opened enrolment for clinical trials in the UK and USA.
Thursday, November 04, 2010
Clinical Trials of New Treatment for Advanced Melanoma in UK and USA
Researchers at Immunocore Limited have announced that IMCgp100, a targeted therapeutic for the treatment of advanced metastatic melanoma, has received regulatory and ethics approval and has opened enrolment for clinical trials in the UK and USA.
Thursday, October 28, 2010
Scientific News
Gut Bacteria Older than Human Species
Some bacteria have lived in the human gut since before we were human, suggesting evolution could have a larger role inhuman bacterial makeup.
Evidence of Mosquito Transmitting Zika
A direct link between the Yellow fever mosquito and Zika transmission has been found following investigation into selective mosquito control.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Mapping Zika’s Routes to Developing Fetus
UC researchers show how Zika virus travels from a pregnant woman to her fetus, and also identified a drug that could stop it.
Treating HIV with Cancer-Fighting Gene Shows Promise
A type of gene immunotherapy that has shown promising results against cancer could also be used against HIV.
Protein Teams Activate T-Cells
Caltech researchers have discovered T-cell genetic switching is controlled by four proteins acting in a multi-tiered fashion.
'Antigen-Presenting Cell' Defends Against Cancer
Through advanced imaging, researchers have identified cells that encourages increases in immune system cancer defences.
Zika Epidemic Likely to End Within Three Years
A team of scientists has predicted that the current Zika epidemic is likely to end within three years because there will be too few people left to infect.
Go-Between Immune Cell is Key to Priming the Body’s Fight Against Cancer
‘Antigen-presenting cell’ activates T cells by alerting them to the presence of tumors.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!